HK1213830A1 - 用於預測醋酸格拉替雷臨床反應的生物標誌物 - Google Patents
用於預測醋酸格拉替雷臨床反應的生物標誌物Info
- Publication number
- HK1213830A1 HK1213830A1 HK16101880.3A HK16101880A HK1213830A1 HK 1213830 A1 HK1213830 A1 HK 1213830A1 HK 16101880 A HK16101880 A HK 16101880A HK 1213830 A1 HK1213830 A1 HK 1213830A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- clinical response
- glatiramer acetate
- biomarkers predictive
- biomarkers
- predictive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712146P | 2012-10-10 | 2012-10-10 | |
| PCT/US2013/064055 WO2014058976A2 (en) | 2012-10-10 | 2013-10-09 | Biomarkers predictive for clinical response for glatiramer acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1213830A1 true HK1213830A1 (zh) | 2016-07-15 |
Family
ID=50475896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16101880.3A HK1213830A1 (zh) | 2012-10-10 | 2016-02-19 | 用於預測醋酸格拉替雷臨床反應的生物標誌物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9617596B2 (zh) |
| EP (1) | EP2906719A4 (zh) |
| AR (1) | AR092981A1 (zh) |
| CA (1) | CA2884267A1 (zh) |
| HK (1) | HK1213830A1 (zh) |
| IL (1) | IL237744A0 (zh) |
| MX (1) | MX2015004563A (zh) |
| NZ (1) | NZ630421A (zh) |
| TW (1) | TW201420111A (zh) |
| UY (1) | UY35075A (zh) |
| WO (1) | WO2014058976A2 (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ30474U1 (cs) | 2009-08-20 | 2017-03-14 | Yeda Research And Development Co., Ltd. | Glatiramer acetát a terapeutická kompozice s jeho obsahem pro použití k léčení s nízkou frekvencí ošetření |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| NZ609938A (en) | 2010-10-11 | 2015-11-27 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| US8815511B2 (en) | 2011-10-10 | 2014-08-26 | Teva Pharmaceutical Industries, Ltd. | Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate |
| TW201420111A (zh) | 2012-10-10 | 2014-06-01 | Teva Pharma | 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記 |
| CA2903805A1 (en) | 2013-03-14 | 2014-10-02 | Mylan Inc. | Glatiramer acetate response biomarker mrna potency assay |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| CA2928084A1 (en) | 2013-10-24 | 2015-04-30 | Mylan Inc. | Human t cell line assay for evaluating the immunologic identity of glatiramer acetate preparations |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| EP3600553A4 (en) | 2017-03-26 | 2020-09-02 | Mapi Pharma Ltd. | GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| CA2337688C (en) | 1998-07-23 | 2016-04-05 | Yeda Research And Development Co., Ltd. | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| WO2000005249A2 (en) | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| EP2090583B1 (en) | 1998-09-25 | 2011-07-13 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| WO2000020010A1 (en) | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| EP1128839A4 (en) | 1998-11-12 | 2002-10-09 | Yeda Res & Dev | PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD |
| ZA200206457B (en) | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
| DE60120648D1 (de) | 2000-02-18 | 2006-07-27 | Yeda Res & Dev | Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung |
| HUP0302333A3 (en) | 2000-06-05 | 2005-07-28 | Teva Pharma | The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| WO2003048735A2 (en) | 2001-12-04 | 2003-06-12 | Teva Pharmaceutical Industries, Ltd. | Processes for the measurement of the potency of glatiramer acetate |
| WO2004028339A2 (en) | 2002-09-27 | 2004-04-08 | Brigham And Women's Hospital, Inc. | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues |
| CA2513567C (en) | 2003-01-21 | 2012-10-23 | Yeda Research And Development Co. Ltd. | Cop 1 for treatment of inflammatory bowel diseases |
| EP1603530A1 (en) | 2003-03-04 | 2005-12-14 | Teva Pharmaceutical Industries Limited | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| PL1638589T3 (pl) | 2003-05-14 | 2014-10-31 | Teva Pharmaceutical Industries Ltd | Terapia kombinowana obejmująca octan glatirameru i mitoksantron do leczenia stwardnienia rozsianego |
| KR20060097020A (ko) | 2003-10-31 | 2006-09-13 | 테바 파마슈티컬 인더스트리즈 리미티드 | 약물 전달용 나노입자 |
| WO2005084377A2 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| CA2579038A1 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| CA2579656C (en) | 2004-09-09 | 2014-11-04 | Teva Pharmaceutical Industries, Ltd. | Process for preparation of mixtures of polypeptides using purified hydrobromic acid |
| US7560100B2 (en) | 2004-09-09 | 2009-07-14 | Yeda Research And Development Co., Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases |
| UA93669C2 (ru) | 2005-02-02 | 2011-03-10 | Тева Фармасьютикл Индастриз, Лтд. | Способ приготовления полипептидной смеси c использованием гидрогенолиза |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| CA2596664A1 (en) | 2005-02-17 | 2006-08-24 | Teva Pharmaceutical Industries Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| CA2606194A1 (en) | 2005-04-25 | 2006-11-02 | Yeda Research And Development Company | Markers associated with the therapeutic efficacy of glatiramer acetate |
| US20070059798A1 (en) | 2005-09-09 | 2007-03-15 | Alexander Gad | Polypeptides useful for molecular weight determinations |
| US20070161566A1 (en) | 2006-01-11 | 2007-07-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| WO2007146331A1 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| US20100209914A1 (en) | 2007-05-25 | 2010-08-19 | Ore Pharmaceuticals , Inc. | Methods, systems, and kits for evaluating multiple sclerosis |
| WO2008157697A2 (en) | 2007-06-21 | 2008-12-24 | Momenta Pharmaceuticals, Inc. | Copolymer assay |
| JP2011504925A (ja) | 2007-11-28 | 2011-02-17 | テバ ファーマシューティカル インダストリーズ リミティド | 臨床的に確実な多発性硬化症の発症を遅延させる方法 |
| WO2010113096A1 (en) | 2009-03-30 | 2010-10-07 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods of predicting clinical course and treating multiple sclerosis |
| RS52367B (en) | 2009-07-15 | 2012-12-31 | Teva Pharmaceutical Industries Ltd. | GLATIRAMER ACETATE FORMULATION FORMATED VOLUMES AND APPLICATION PROCEDURES |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| CZ30474U1 (cs) | 2009-08-20 | 2017-03-14 | Yeda Research And Development Co., Ltd. | Glatiramer acetát a terapeutická kompozice s jeho obsahem pro použití k léčení s nízkou frekvencí ošetření |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| US8765398B2 (en) | 2010-05-12 | 2014-07-01 | Mesa Laboratories, Inc. | Biological indicator with integral package |
| AU2011253481A1 (en) * | 2010-05-12 | 2013-01-10 | Steven E. Schutzer | Diagnostic markers for neuropsychiatric disease |
| NZ609938A (en) * | 2010-10-11 | 2015-11-27 | Teva Pharma | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| US8815511B2 (en) | 2011-10-10 | 2014-08-26 | Teva Pharmaceutical Industries, Ltd. | Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate |
| TW201420111A (zh) | 2012-10-10 | 2014-06-01 | Teva Pharma | 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記 |
| KR20150111945A (ko) | 2013-01-04 | 2015-10-06 | 테바 파마슈티컬 인더스트리즈 리미티드 | 글라티라머 아세테이트 관련 완제의 특성조사 |
| AR095372A1 (es) | 2013-03-12 | 2015-10-14 | Teva Pharma | Terapia de inducción con rituximab seguida por una terapia con acetato de glatiramer |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
-
2013
- 2013-10-09 TW TW102136605A patent/TW201420111A/zh unknown
- 2013-10-09 US US14/050,195 patent/US9617596B2/en not_active Expired - Fee Related
- 2013-10-09 EP EP13845054.9A patent/EP2906719A4/en not_active Withdrawn
- 2013-10-09 WO PCT/US2013/064055 patent/WO2014058976A2/en active Application Filing
- 2013-10-09 NZ NZ630421A patent/NZ630421A/en not_active IP Right Cessation
- 2013-10-09 CA CA2884267A patent/CA2884267A1/en not_active Abandoned
- 2013-10-09 MX MX2015004563A patent/MX2015004563A/es unknown
- 2013-10-10 AR ARP130103692A patent/AR092981A1/es unknown
- 2013-10-10 UY UY0001035075A patent/UY35075A/es not_active Application Discontinuation
-
2015
- 2015-03-15 IL IL237744A patent/IL237744A0/en unknown
-
2016
- 2016-02-19 HK HK16101880.3A patent/HK1213830A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2906719A2 (en) | 2015-08-19 |
| IL237744A0 (en) | 2015-05-31 |
| AR092981A1 (es) | 2015-05-13 |
| EP2906719A4 (en) | 2016-11-09 |
| MX2015004563A (es) | 2015-07-14 |
| TW201420111A (zh) | 2014-06-01 |
| UY35075A (es) | 2014-04-30 |
| US20140107208A1 (en) | 2014-04-17 |
| CA2884267A1 (en) | 2014-04-17 |
| NZ630421A (en) | 2018-07-27 |
| US9617596B2 (en) | 2017-04-11 |
| WO2014058976A2 (en) | 2014-04-17 |
| WO2014058976A3 (en) | 2015-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1213830A1 (zh) | 用於預測醋酸格拉替雷臨床反應的生物標誌物 | |
| ZA201500384B (en) | Clinical predictive analytics system | |
| EP2901333A4 (en) | PREDICTIVE PREACHING DATA BASED ON THE CONTEXT | |
| EP2807477A4 (en) | analyte | |
| EP2852834A4 (en) | CLINICAL DIAGNOSTIC SYSTEMS | |
| GB2504570B (en) | Microtome having an auto-rocking mode | |
| EP2888131A4 (en) | PREDICTIVE PARKING | |
| GB201213567D0 (en) | Biomarkers | |
| EP2748335A4 (en) | URINBIOMARKER | |
| GB201211982D0 (en) | Biomarker | |
| ZA201404463B (en) | Detecting analytes | |
| EP2627669A4 (en) | BIOLOGICAL MARKERS BASED ON CYTOKINE AS BIOLOGICAL MARKERS PREDICTIVE OF CLINICAL RESPONSE TO GLATIRAMÈRE ACETATE | |
| ZA201409006B (en) | Diabetes biomarkers | |
| IL233794B (en) | Antibody against phospholipase d4 | |
| EP2828282A4 (en) | BIOMARKERS | |
| HK1202899A1 (zh) | 糖尿病的生物標誌物 | |
| GB201210565D0 (en) | Biomarkers | |
| SG11201502390QA (en) | Biomarkers for down syndrome prenatal diagnosis | |
| GB201113968D0 (en) | Prognostic methadology | |
| GB201104556D0 (en) | Biomarkers | |
| GB201210587D0 (en) | Predictive biomarker | |
| GB201209802D0 (en) | Biomarker | |
| EP2883052B8 (en) | Biomarkers | |
| GB201210571D0 (en) | Predictive biomarker | |
| GB201209420D0 (en) | Prognostic gene |